Patents by Inventor Lieming Ding

Lieming Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound functioning as bromodomain protein inhibitor, and composition
    Patent number: 11845762
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: December 19, 2023
    Assignee: BETTA PHARMACEUTICALS CO., LTD.
    Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
  • BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF
    Publication number: 20230391779
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions comprising such compounds and use thereof. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 7, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiaofeng XU, Jinheng GAO, Hongfei RONG, Xizhen SONG, Jie CHEN, Xiangyong LIU, Hongling SHEN, Jing GUO, Dan YAN, Hong LAN, Lieming DING, Jiabing WANG
  • SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF
    Publication number: 20230339882
    Abstract: A compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treating an SHP2 mediation diseases. The compounds of formula I exerts an effect by means of participating in the regulation of multiple processes such as cell proliferation, apoptosis, migration, and angiogenesis.
    Type: Application
    Filed: July 22, 2021
    Publication date: October 26, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Hao WU, Wenmao WU, Ling LI, Zhan ZHANG, Feng WANG, Ding YUAN, Yunfei WU, Qiang CHEN, Han HAN, Jing GUO, Hong LAN, Lieming DING, Jiabing WANG
  • CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE
    Publication number: 20230321100
    Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition comprising the compound.
    Type: Application
    Filed: September 6, 2021
    Publication date: October 12, 2023
    Inventors: Hao WU, Xiaofeng YANG, Qisheng LIU, Han HAN, Jinhua LI, Yang LI, Feng JIANG, Cuiwen KUANG, Hongfeng XIA, Hongbo ZHANG, Hong LAN, Jiabing WANG, Lieming DING
  • BICYCLIC COMPOUNDS AND USE THEREOF
    Publication number: 20230219890
    Abstract: The present invention relates to a compound as represented by formula (I). The present invention also provides compositions and formulations containing such compounds, and methods for using and preparing such compounds.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 13, 2023
    Inventors: Rongwen YANG, Yun SUN, Jian ZHANG, Xiangkai LIU, Pingping WANG, Xuegang YI, Teng MA, Chuanlong HUANG, Hong LAN, Lieming DING, Jiabing WANG
  • QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF
    Publication number: 20230219956
    Abstract: The present invention relates to a novel compound, which has cancer therapeutic activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound.
    Type: Application
    Filed: April 20, 2020
    Publication date: July 13, 2023
    Inventors: Hao WU, Yuan LU, Jun YU, Xiao ZHOU, Boyan LI, Jiangqi HE, Shuibiao FU, Rongwen YANG, Yabin LI, Chao WANG, Jiabing WANG, Hong LAN, Lieming DING
  • FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE
    Publication number: 20230203055
    Abstract: The present invention relates to a novel compound (formula I), which has cancer treatment activity. The present invention also relates to a preparation method for the compound and a pharmaceutical composition containing the compound.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 29, 2023
    Inventors: Hao Wu, Xiaoping Chen, Jun Yu, Yuan Lu, Jiangqi He, Wei Wang, Bo Zhan, Boyan Li, Yunlai Zhang, Dong Wang, Xiujun Xie, Xiaoguan Zhu, Hong Lan, Jiabing Wang, Lieming Ding
  • SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF
    Publication number: 20230192705
    Abstract: Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.
    Type: Application
    Filed: June 10, 2021
    Publication date: June 22, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Bang FU, Zhongxin SUN, Xiaofeng XU, Wei REN, Yinlong LI, Ling LI, Lieming DING, Jiabing WANG
  • EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF
    Publication number: 20230133169
    Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 4, 2023
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Xiangyong LIU, Changyong QIU, Guolong DU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Lieming DING, Jiabing WANG
  • QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF
    Publication number: 20230131025
    Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 27, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiangyong LIU, Changyong QIU, Mengqiang LIU, Xiaodong SONG, Qichao SHEN, Guolong DU, Haitong SHENG, Lieming DING, Jiabing WANG
  • KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230062486
    Abstract: Provided are compounds of formula (I), which have KRAS mutation tumor regulating activity. Also provided are a method for providing these compounds and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Inventors: Hao Wu, Xiaoping Chen, Yuan Lu, Jun Yu, Xiujun Xie, Jiangqi He, Shuibiao Fu, Qi Shen, Letian Zhang, Xiaoguan Zhu, Hong Lan, Jiabing Wang, Lieming Ding
  • IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230053342
    Abstract: An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthesis method therefor and use thereof.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 23, 2023
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Houxian ZU, Xizhen SONG, Kai CHEN, Xiangyong LIU, Jie CHEN, Yajing BIAN, Lieming DING, Jiabing WANG
  • COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION
    Publication number: 20230022091
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Application
    Filed: August 29, 2022
    Publication date: January 26, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yan XU, Xiaofeng XU, Jiabing WANG, Lieming DING
  • EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR
    Publication number: 20220402948
    Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 22, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Haitong SHENG, Mengqiang LIU, Qichao SHEN, Guolong DU, Xiaodong SONG, Lieming DING, Jiabing WANG
  • ERK inhibitor and use thereof
    Patent number: 11466013
    Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd
    Inventors: Hao Wu, Wei Gu, Xiaojing Tang, Wei Wang, Bo Zhan, Dongjie Feng, Yongxin Ke, Zhongyan Chen, Yifei Shen, Wenmao Wu, Xintao Zhao, Hong Lan, Jiabing Wang, Lieming Ding
  • Compound functioning as bromodomain protein inhibitor, and composition
    Patent number: 11466034
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
  • EGFR Inhibitor, Composition, and Preparation Method Therefor
    Publication number: 20220259235
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 23, 2020
    Publication date: August 18, 2022
    Inventors: Xiangyong Liu, Changyong Qiu, Qichao Shen, Mengqiang Liu, Haitong Sheng, Xiaodong Song, Guolong Du, Jiabing Wang, Lieming Ding
  • EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF
    Publication number: 20220227796
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 21, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Guolong DU, Jiabing WANG, Lieming DING
  • FGFR inhibitor and application thereof
    Patent number: 11365196
    Abstract: An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 21, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiaofeng Xu, Jiabing Wang, Lieming Ding, Xiangyong Liu
  • IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220119411
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 12, 2019
    Publication date: April 21, 2022
    Inventors: Bang FU, Yao ZHANG, Yiqian WANG, Xiangyong LIU, Jiabing WANG, Lieming DING